Patient dosing underway in phase 2 trial of DME candidate

The first patient has been dosed in a phase 2 clinical trial investigating EYP-1901 for the treatment of diabetic macular edema (DME), according to a press release from EyePoint Pharmaceuticals. EYP-1901 is an investigational therapy containing vorolanib, which inhibits pathways with key roles in the development of abnormal blood vessels and pathological blood vessel leakage, packaged in a solid bioerodable insert. It is hoped that a single dose will provide six months of treatment. The company expects to enroll approximately 25 patients in the randomized, controlled, single-masked VERONA trial. Patients will receive either one of two doses of EYP-1901 or the anti-VEGF drug aflibercept as a control. The primary efficacy endpoint is the time to first supplemental aflibercept injection up to 24 weeks. Secondary endpoints will assess safety, change in visual acuity, change in central subfield thickness, an anatomical marker of DME, and change in Diabetic Retinopathy Severity Scale, a standardized scale that classifies diabetic retinopathy severity. EyePoint expects topline data from the trial in 2025.

For more information about this trial, visit

Source:  Healio, January 12, 2024; see source article